A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a multi-center, open-label, Phase 1/2 study to evaluate the safety, tolerability, Pharmacokinetics, pharmacodynamics and Preliminary Efficacy of CM313 in Subjects with Relapsed or Refractory Multiple Myeloma.
Multiple Myeloma
BIOLOGICAL: CM313 injection
Adverse event, Incidence, severity, and outcome of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), up to 18 months
This is a multi-center, open-label, Phase 1/2 study to evaluate the safety, tolerability, Pharmacokinetics, pharmacodynamics and Preliminary Efficacy of CM313 in Subjects with Relapsed or Refractory Multiple Myeloma.